Abiraterone survival benefit is independent of pain, prostate-specific antigen and Gleason sum in men with chemo-nave metastatic castration-resistant prostate cancer (analysis of COU-AA-302)doi:10.21037/AMJ.2018.03.16Panagiotis J. Vlachostergios...
agents able to interfere with the AR-pathway in metastatic TNBC, notably: abiraterone acetate, an oral agent that inhibits androgen biosynthesis by inhibiting 17α-hydroxylase/C17,20-lyase (CYP17); bicalutamide, a non-steroidal anti-androgen; and enzalutamide, a potent oral androgen receptor ...